Assistant Professor of Biochemistry and Molecular Genetics
Bio
The misregulation of histone and DNA modifiers has emerged as a common therapeutic target for treating various human diseases, including cancer. My laboratory aims to understand the relationship between dysregulated epigenetic factors and cancer development through advanced technologies such as genome-wide CRISPR screening and high-throughput small-molecule inhibitor screening. This research could guide us in identifying the druggability of specific epigenetic factors, paving the way for novel, more precise cancer treatments that can be translated into clinical applications.
Approximately 70% of all breast cancers are due to hormone receptor (ER)-positive BCa. Currently, ER+ BCa diagnosed patients can be treated with hormone therapy via drugs, such as tamoxifen. However, this type of breast cancer can lead to recurrences many years after treatment. In this particular study, we have developed a new therapy by targeting metabolic signaling to overcome endocrine resistance in breast cancer.
Lu Wang, PhD
Northwestern University Feinberg School of Medicine
Newly funded researchers pursuing high-risk, high-reward breast cancer studies in their first or second academic positions.
Past
Early Investigator
Abde Abukhdeir, PhD
The molecular variants that lead or contribute to drug resistance in breast cancer
Past
Early Investigator
Nan Chen, MD
Discovering novel biomarkers of therapy response and resistance in metastatic triple-negative breast cancer patients
Past
Early Investigator
Peiwen Chen, PhD
Targeting macrophage reprogramming in brain metastatic breast cancer
Why your gift matters
Your gift helps researchers test bold ideas, generate critical data, and take the first steps toward the next major advancement in breast cancer treatment and care.Together, we can accelerate discoveries that save lives.
